15 July 2022 in Protein & Cell
The tricarboxylic acid (TCA) cycle identified in 1937 by Hans Adolf Krebs and William Arthur Johnson (also known as the Krebs cycle or citric acid cycle) is a central route for oxidative metabolism to generate cellular energy and intermediates for the biosynthesis of amino acids, lipids, and nucleic acids ( Krebs and Johnson 1937). The TCA cycle connects carbohydrate, fat, and protein metabolism and converts these nutrient catabolism-derived acetyl-CoA into carbon dioxide and water, with the production of reduced NAD+ (NADH), reduced flavin adenine dinucleotide (FADH2), and guanosine triphosphate (GTP). The generated NADH and FADH2 are, in turn, used by the oxidative phosphorylation pathway to generate energy-rich adenosine triphosphate (ATP) ( Chakrabarty and Chandel 2021).
28 November 2023 in Hepatology
Background and Aims: Base editing has shown great potential for treating human diseases with mutated genes. However, its potential for treating HCC has not yet been explored. Approach and Results: We employed adenine base editors (ABEs) to correct a telomerase reverse transcriptase (TERT) promoter mutation, which frequently occurs in various human cancers, including HCC. The mutated TERT promoter −124 C>T is corrected to −124 C by a single guide (sg) RNA-guided and deactivated Campylobacter jejuni Cas9 (CjCas9)-fused adenine base editor (CjABE). This edit impairs the binding of the E-twenty six/ternary complex factor transcription factor family, including E-twenty six-1 and GABPA, to the TERT promoter, leading to suppressed TERT promoter and telomerase activity, decreased TERT expression and cell proliferation, and increased cell senescence. Importantly, injection of adeno-associated viruses expressing sgRNA-guided CjABE or employment of lipid nanoparticle-mediated delivery of CjABE mRNA and sgRNA inhibits the growth of liver tumors harboring TERT promoter mutations. Conclusions: These findings demonstrate that a sgRNA-guided CjABE efficiently converts the mutated TERT promoter −124 C>T to −124 C in HCC cells and underscore the potential to treat HCC by the base editing-mediated correction of TERT promoter mutations.
6 March 2025 in Journal of Experimental Medicine
Hypoxia induces immunosuppressive phenotypes in tumor cells even in the presence of cytosolic DNA accumulation. The mechanisms by which tumor cells suppress hypoxia-induced cGAS-STING activation for immune evasion remain largely unclear. Here, we demonstrate that hypoxic stimulation induces JNK1/2-mediated S151 phosphorylation of phosphoenolpyruvate carboxykinase 1 (PCK1), a rate-limiting enzyme in gluconeogenesis. This phosphorylation triggers the interaction between PCK1 and cGAS. The PCK1 associated with cGAS competitively consumes GTP, a substrate shared by both PCK1 and cGAS. Consequently, PCK1 inhibits GTP-dependent cGAS activation and subsequent STING-promoted immune cell infiltration and activation in the tumor microenvironment, leading to promoted tumor growth in mice. The blockade of PCK1 function, in combination with anti–PD-1 antibody treatment, exhibits an additive therapeutic effect on tumor growth. Additionally, PCK1 S151 phosphorylation is inversely correlated with cGAS-STING activation in human breast cancer specimens and patient survival. These findings reveal a novel regulation of cGAS-STING pathway and uncover the metabolic control of immune response in tumor cells.